Company intelligence / Profile preview

Arch Biosurgery

Framingham, Massachusetts, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Arch Therapeutics is developing novel hemostatic and sealant devices based on self-assembling barrier technology. In preclinical tests, the AC5 Surgical Hemostatic Device has demonstrated effectiveness, biocompatibility, and normal tissue healing. The company has received regulatory authorization to market AC5 Advanced Wound System in the United States and AC5 Topical Hemostat in Europe as medical devices[1].

Therapeutic areas: HematologyDermatology
Modalities: Device
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on Arch Biosurgery.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arch Biosurgery.

Explore the full profile